Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by PharmaEssentia Corporation

CORRECTING and REPLACING PharmaEssentia Announces Positive Topline Phase 3 Data from SURPASS-ET Study Evaluating Ropeginterferon Alfa-2b-njft (P1101) for Essential Thrombocythemia
From PharmaEssentia Corporation
Via Business Wire
PharmaEssentia to Present at the Annual J.P. Morgan Healthcare Conference on January 16, 2025
From PharmaEssentia Corporation
Via Business Wire
PharmaEssentia Appoints Joseph R. Horvat as Global Chief Commercial Officer
From PharmaEssentia Corporation
Via Business Wire
PharmaEssentia Announces Nine Data Presentations at ASH Annual Meeting
From PharmaEssentia Corporation
Via Business Wire
PharmaEssentia Announces Licensing Agreement with FORUS Therapeutics to Commercialize BESREMi® (ropeginterferon alfa-2b-njft) in Canada
From PharmaEssentia Corporation
Via Business Wire
PharmaEssentia Appoints Beth A. Krewson as Head of Legal
From PharmaEssentia Corporation
Via Business Wire
PharmaEssentia Promotes Robert B. Geller, M.D. to General Manager
From PharmaEssentia Corporation
Via Business Wire
PharmaEssentia Completes Patient Enrollment for Phase 2b EXCEED-ET Trial in Essential Thrombocythemia and Phase 3b ECLIPSE-PV Trial in Polycythemia Vera
From PharmaEssentia Corporation
Via Business Wire
Analyses Find Patients With Polycythemia Vera (PV) Treated With BESREMi® (ropeginterferon alfa-2b) Had Increased Probability of Achieving Complete Hematologic Response
From PharmaEssentia Corporation
Via Business Wire
PharmaEssentia’s BESREMi (ropeginterferon alfa-2b-njft) Now Recommended as a Preferred First-line Cytoreductive Therapy for Polycythemia Vera in Updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
From PharmaEssentia Corporation
Via Business Wire
Clinical Review of Pegylated Interferons Suggests Formulation and Mechanism of Action May Improve Outcomes for MPN Patients
From PharmaEssentia Corporation
Via Business Wire
PharmaEssentia Enters Into Exclusive Global License Agreement With WuXi Biologics for a Myeloid Immune Checkpoint Antibody Candidate
From PharmaEssentia Corporation
Via Business Wire
PharmaEssentia Included in FTSE Russell Indices
From PharmaEssentia Corporation
Via Business Wire
New ropeginterferon alfa-2b Data Suggest Alternate Dosing Schedule May Achieve Greater and Quicker Complete Hematologic and Molecular Responses in Polycythemia Vera
From PharmaEssentia Corporation
Via Business Wire
PharmaEssentia Selects Pint-Pharma as Commercial Partner for BESREMi® (ropeginterferon alfa-2b-njft) in Latin America
From PharmaEssentia Corporation
Via Business Wire
PharmaEssentia Corporation Announces Closing of Global Depositary Receipt Offering, Generating US$462.7M to Support Growth Plans and Pipeline Development
From PharmaEssentia Corporation
Via Business Wire
PharmaEssentia Establishes a New Research and Development Facility in the Boston Area
From PharmaEssentia Corporation
Via Business Wire
PharmaEssentia to Present at the 41st Annual J.P. Morgan Healthcare Conference
From PharmaEssentia Corporation
Via Business Wire
Pharmaessentia to Host Investor Day in New York City on November 30, 2022
From PharmaEssentia Corporation
Via Business Wire
PharmaEssentia USA Expands Leadership With Executive Hires in Marketing, Medical Affairs and Communications and Advocacy
From PharmaEssentia Corporation
Via Business Wire
Review of SURPASS-ET Trial Evaluating Ropeginterferon Alfa-2b-njft for Essential Thrombocythemia (ET) Published in Future Oncology
From PharmaEssentia Corporation
Via Business Wire
PharmaEssentia Appoints Dr. Lih-Ling Lin as Chief Scientific Officer
From PharmaEssentia Corporation
Via Business Wire
PharmaEssentia Honored at the National Organization of Rare Disorders (NORD®) 2022 Rare Impact Awards for the Introduction of BESREMi® (ropeginterferon alfa-2b-njft) for Polycythemia Vera
From PharmaEssentia Corporation
Via Business Wire
New Data on Ropeginterferon Alfa-2b to Be Featured at EHA2022
From PharmaEssentia Corporation
Via Business Wire
U.S. FDA Approves BESREMi® (ropeginterferon alfa-2b-njft) as the Only Interferon for Adults With Polycythemia Vera
From PharmaEssentia Corporation
Via Business Wire
PharmaEssentia Announces Pipeline Presentation During Upcoming American Society of Hematology Annual Meeting
From PharmaEssentia Corporation
Via Business Wire
PharmaEssentia Resubmits Application to the U.S. FDA For Ropeginterferon alfa-2b-njft to Treat Polycythemia Vera (PV)
From PharmaEssentia Corporation
Via Business Wire
Dr. Norio Komatsu Appointed as a Chairperson of PharmaEssentia Japan
From PharmaEssentia Corporation
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.